Table 2.

Clinical trials evaluating the efficacy of ACE2-ralated therapy and RAS drugs in SARS-CoV-2 pneumonia treatment.

Clinical Trials Identifier	Study Title	Interventional Drug	Interventional Study Design
NCT04351581	Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2	rbACE2 plus Aerosolized Isotretinoin	Randomized Parallel Assignment Open Label
NCT04355936	Telmisartan for Treatment of COVID-19 Patients	Telmisartan	Randomized Parallel Assignment Open Label
NCT04335786	Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients with SARS-CoV-2 (COVID-19) Infection Disease	Valsartan	Randomized Parallel Assignment Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
NCT04312009	Losartan for Patients with COVID-19 Requiring Hospitalization	Losartan	Randomized Parallel Assignment Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
NCT04311177	Losartan for Patients with COVID-19 Not Requiring Hospitalization	Losartan	Randomized Parallel Assignment Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
NCT04328012	COVID MED Trial-Comparison of Therapeutics for Hospitalized Patients Infected with SARS-CoV-2	Losartan combined with lopinavir/ritonavir	Randomized Parallel Assignment Double blind, placebo controlled
NCT04340557	Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome with SARS-CoV-2 Infection	Losartan	Randomized Parallel Assignment Open Label
NCT04332666	Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (ATCO)	Angiotensin 1–7	Randomized Parallel Assignment Triple (Participant, Investigator, Outcomes Assessor)